Laboratory assessment of the status of Her-2/neu protein and oncogene in breast cancer specimens: comparison of immunohistochemistry assay with fluorescence in situ hybridisation assays.

@article{Wang2000LaboratoryAO,
  title={Laboratory assessment of the status of Her-2/neu protein and oncogene in breast cancer specimens: comparison of immunohistochemistry assay with fluorescence in situ hybridisation assays.},
  author={Shixuan Wang and Mohammad Hossein Saboorian and Eugene P. Frenkel and Linda S. Hynan and S T Gokaslan and Raheela Ashfaq},
  journal={Journal of clinical pathology},
  year={2000},
  volume={53 5},
  pages={
          374-81
        }
}
AIM To evaluate the clinical usefulness of three commercially available assays for Her-2/neu oncogene and protein measurements. The Her-2/neu protein is overexpressed, mostly as a result of gene amplification, in 20-30% of human breast cancers, and has been shown to have prognostic and predictive value for treatment with chemotherapy or the new monoclonal antibody, Herceptin. METHODS An immunohistochemistry (IHC) assay using the Dako polyclonal antibody A0485, which measures the Her-2/neu… CONTINUE READING

Similar Papers

Citations

Publications citing this paper.
SHOWING 1-10 OF 66 CITATIONS, ESTIMATED 36% COVERAGE

Real-time PCR technology for cancer diagnostics.

  • Clinical chemistry
  • 2002
VIEW 9 EXCERPTS
CITES METHODS
HIGHLY INFLUENCED

FILTER CITATIONS BY YEAR

2000
2018

CITATION STATISTICS

  • 3 Highly Influenced Citations

References

Publications referenced by this paper.
SHOWING 1-10 OF 25 REFERENCES

Fluorescent in situ hybridization ( FISH ) vs immunohistochemistry ( IHC ) for determination of Her 2 / neu status in breast cancer [ abstract 116 ]

RE Jimenez, T Wallis, P Tabaczka
  • Mod Pathol
  • 1999

Her - 2 / neu oncogene overexpression : comparison of immunohistochemistry ( IHC ) with fluorescent in situ hybridization assay ( FISH ) [ abstract 70 ]

R Ashfaq, E Frenkel, F Saliger
  • Mod Pathol
  • 1999

Her 2 / neu protein expression in breast cancer determined by immunohistochemistry ( IHC ) : a study of interlaboratory agreement [ abstract 113 ]

TW Jacobs, M Barnes, H Yaziji
  • Mod Pathol
  • 1999

Increased HER2 with U.S. Food and Drug Administration-approved antibody.

  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 1999

Prognostic and predictive factors in breast cancer by immunohistochemical analysis.

  • Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • 1998